Security Snapshot

Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") (LKFT) Institutional Ownership

CUSIP: 36315X101

13F Institutional Holders and Ownership History from Q2 2015 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

76

Shares (Excl. Options)

32.06MFull value: 32,057,062 · shares · 30 Jun 2026

Price

$29.98

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Ordinary shares, no nominal value per share (the "Ordinary Shares")
Symbol
LKFT on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
32,057,062
Latest holder snapshot 5 signals
Total 13F value
$960,330,120
Portfolio coverage rank
0%
Share change
+798,712
Value change
+$23,929,397
Number of holders
76
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
65,567,327
SEC-reported price per share
$29.51
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • LKFT - Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") is tracked under CUSIP 36315X101.
  • 76 institutions reported positions in Q2 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 90 to 76 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $937.85MFull value: $937,850,803 · USD · 31 Mar 2026
    to
    $960.33MFull value: $960,330,120 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 76 institutions filings for Q2 2026.

Open SEC evidence

Security key

36315X101

13F reference period

Q2 2026

13F holders

76

13D/G owners

4

CIK / CUSIP context first

Open Q2 2026 holders LKFT full holder history Lakefront Biotherapeutics NV SEC filings Lakefront Biotherapeutics NV company facts

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
LKFT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 30% $555,786,955 20,981,010 Gilead Sciences, Inc. 07 Jan 2025
EcoR1 Capital, LLC 13% +12% $243,919,471 +$25,507,847 8,714,522 +12% EcoR1 Capital, LLC 24 Jul 2025
TANG CAPITAL MANAGEMENT LLC 8.4% +11% $192,587,107 +$22,486,521 5,559,674 +13% TANG CAPITAL MANAGEMENT, LLC 27 Oct 2025
Madison Avenue Partners, LP 5.5% $95,961,062 3,606,203 Madison Avenue International LP 15 Jun 2026
As of 30 Jun 2026, 76 institutional investors reported holding
32.06MFull value: 32,057,062 · shares · 30 Jun 2026
shares of Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") (LKFT). This represents 49% of the company’s total
65.57MFull value: 65,567,327 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
49%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 25% 16,707,477 0% 30% $500,157,715
TANG CAPITAL MANAGEMENT LLC 5.8% 3,785,991 0% 5.2% $113,504,010
Madison Avenue Partners, LP 5.3% 3,447,807 +40% 4.4% $103,365,254
Prosight Management, LP 3.1% 2,043,344 +32% 11% $61,259,453
EcoR1 Capital, LLC 2.5% 1,667,119 0% 2.5% $49,980,228
AMERIPRISE FINANCIAL INC 1.9% 1,272,249 -11% 0.01% $38,140,727
DME Capital Management, LP 0.74% 482,746 0% 0.37% $14,472,725
RENAISSANCE TECHNOLOGIES LLC 0.62% 407,800 +29% 0.02% $12,225,844
BlackRock, Inc. 0.52% 338,152 +8.3% 0% $10,137,797
Point72 Asset Management, L.P. 0.41% 269,814 -19% 0.01% $8,089,024
D. E. Shaw & Co., Inc. 0.3% 197,844 -8.3% 0% $5,931,363
MILLENNIUM MANAGEMENT LLC 0.28% 181,090 +68% 0% $5,429,078
UBS Group AG 0.26% 168,148 -4.1% 0% $5,041,077
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.23% 151,886 +1035% 0% $4,553,542
DAFNA Capital Management LLC 0.2% 130,175 0% 0.74% $3,902,647
CITADEL ADVISORS LLC 0.13% 88,343 -29% 0% $2,648,524
TWO SIGMA INVESTMENTS, LP 0.12% 81,749 +216% 0% $2,450,835
NORGES BANK 0.12% 76,879 0% $2,304,832
ALPS ADVISORS INC 0.1% 65,523 +22% 0.01% $1,964,380
GOLDMAN SACHS GROUP INC 0.09% 56,581 +25% 0% $1,696,298
AMERICAN CENTURY COMPANIES INC 0.06% 40,804 +5.2% 0% $1,223,304
BAROMETER CAPITAL MANAGEMENT INC. 0.06% 40,800 +7.1% 0.34% $1,223,184
MORGAN STANLEY 0.06% 37,682 +42% 0% $1,129,706
Schonfeld Strategic Advisors LLC 0.05% 32,597 0.01% $977,256
MARSHALL WACE, LLP 0.05% 32,399 0% $971,321

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
46
Headline period
Q2 2026
Rows shown
1-25 of 46
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 149,535 $4,433,228 +$1,627,352 $29.65 14
2026 Q2 32,057,062 $960,330,120 +$23,929,397 $29.98 76
2026 Q1 31,262,417 $937,850,803 -$1,948,311 $30.00 90
2025 Q4 31,396,165 $1,030,612,133 -$423,032 $32.70 92
2025 Q3 31,401,256 $1,087,732,117 -$7,956,750 $34.64 92
2025 Q2 31,697,765 $887,221,465 +$28,214,019 $27.99 85
2025 Q1 31,070,295 $780,194,528 -$4,334,186 $25.12 82
2024 Q4 31,079,138 $856,919,857 +$17,773,347 $27.50 81
2024 Q3 13,663,353 $393,374,763 -$177,023,110 $28.79 77
2024 Q2 19,935,693 $494,012,131 -$14,463,813 $24.78 82
2024 Q1 20,486,366 $659,634,802 +$21,269,889 $32.20 79
2023 Q4 19,790,623 $804,487,651 +$20,616,236 $40.65 87
2023 Q3 19,171,399 $662,382,310 -$16,486,115 $34.55 72
2023 Q2 19,708,613 $801,351,937 +$60,840,835 $40.66 73
2023 Q1 18,215,508 $703,834,822 +$192,041,792 $38.64 72
2022 Q4 13,177,559 $584,821,554 +$12,983,412 $44.38 71
2022 Q3 12,911,798 $550,549,123 -$12,978,528 $42.64 77
2022 Q2 12,900,644 $719,839,590 -$9,312,560 $55.80 79
2022 Q1 12,830,797 $795,810,983 +$134,250,057 $62.02 86
2021 Q4 10,793,402 $595,046,185 +$111,349,568 $55.13 81
2021 Q3 8,551,124 $449,836,824 +$478,944 $52.61 80
2021 Q2 7,506,771 $517,197,342 +$62,993,693 $68.89 99
2021 Q1 6,565,519 $505,977,352 +$131,911,497 $77.09 123
2020 Q4 4,564,667 $452,130,046 -$397,947,991 $98.98 106
2020 Q3 7,422,842 $1,053,286,217 -$44,029,693 $141.91 116
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .